Personalised Medicine Market Size, Share, Trends & Forecast 2026–2034

Table Of Content

Methodology

Research Methodology

• ZMR's Global Personalised Medicine Market report employs a mixed-method research architecture combining structured primary research, systematic secondary data aggregation, and a proprietary multi-variable forecast modelling framework. The overall approach prioritises data triangulation — cross-referencing independently sourced datasets to validate market sizing and segment estimates before incorporating them into the forecast model.
• Primary research for this report involved structured interviews and expert consultations with a cross-functional stakeholder panel specific to the Personalised Medicine value chain. Respondents included hospital procurement executives and genomics programme directors at major academic medical centres, clinical laboratory directors at independent diagnostic operators, medical affairs heads at precision oncology pharmaceutical companies, regulatory affairs specialists with FDA companion diagnostic submission experience, venture capital investors active in precision medicine and genomics, and medical oncologists at National Cancer Institute-designated cancer centres. Primary data collection targeted commercial adoption patterns, reimbursement decision criteria, technology procurement timelines, and competitive positioning intelligence that cannot be sourced from published databases.
• Secondary research sources for this report include FDA companion diagnostic approval databases and 510(k) clearance records, EMA product approval registers, ClinicalTrials.gov registry data for precision medicine pipeline mapping, peer-reviewed publications in Nature Medicine, Journal of Personalized Medicine, and JAMA Oncology, NIH National Cancer Institute cancer statistics databases, company annual reports and investor day presentations for the 15 profiled companies, regulatory filings from SEC EDGAR for U.S.-listed precision medicine companies, industry association reports from the Personalised Medicine Coalition (PMC) and European Alliance for Personalised Medicine (EAPM), and IMS Health/IQVIA pharmaceutical sales data for relevant drug categories.
• Data validation and forecast modelling for this report employs a three-stage process. Stage 1 applies bottom-up market sizing — aggregating sub-segment revenue estimates from primary interviews and secondary sales data, validated against reported company revenues for the top 15 players. Stage 2 applies a top-down overlay using health system expenditure growth rates, genomic sequencing volume data, and drug approval pipeline projections from FDA regulatory databases to constrain the bottom-up model. Stage 3 triangulates both outputs against historical ZMR precision medicine market tracking data and calibrates the ${M.cagr}% base-case CAGR forecast against conservative (−2%) and optimistic (+2%) scenario bands to produce the reported ${M.period} forecast trajectory.